PFIZER INC (PFE) Stock News
NYSE:PFE - New York Stock Exchange, Inc. - US7170811035 - Common Stock - Currency: USD
PFE Latest News, Press Relases and Analysis
Stay informed about the most active stocks in the S&P500 index on Tuesday's session.
Looking for the most active S&P500 stocks in today's session? Join us as we dive into the US markets on Tuesday and discover the stocks that are dominating the trading activity and setting the pace for the market.
Curious about the most active S&P500 stocks in today's session?
Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention.
Hearing Against Pfizer Set For 30 May In Contraceptive ‘Depo-Provera’ Multidistrict Litigation Overseen By Levin Papantonio
Robert F. Kennedy Jr. Says CDC Drops COVID Vaccine For 'Healthy' Pregnant Women, Children
RFK Jr. says the COVID-19 vaccine is no longer on the CDC's recommended schedule for healthy kids and pregnant women, though the official site still shows it listed.
Was Jim Cramer Right About Enbridge Inc. (ENB)?
We recently published a list of Was Jim Cramer Right About These 11 Stocks? In this article, we are going to take a look at where Enbridge Inc. (NYSE:ENB) stands against other stocks that Jim Cramer discusses. A caller said he sold Dominion Energy and bought Enbridge Inc. (NYSE:ENB), asking whether he should hold and […]
Is Pfizer Stock a Buy After This $1.25 Billion Investment?
Is Pfizer Stock a Buy After This $1.25 Billion Investment?
Pfizer is licensing a promising investigational cancer medicine from a smaller company. This move improves the drugmaker's already attractive oncology pipeline. Pfizer should eventually bounce back, thanks to its deep pipeline and improving efficiency.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
US Corporate Giants Tap Euro Debt Market
A surge in US companies issuing euro-denominated debt has seen some €40 billion borrowed at a record pace this year. The post US Corporate Giants Tap Euro Debt Market appeared first on The Daily Upside.
Target Stock Looks Cheap but It May Be a Bargain Today for a Much Better Reason
Target's stock has dropped to cheap levels because of slumping sales and worries over higher costs. Investors could be under-appreciating this one opportunity that's already boosting profits for Target's top peers in the retail space. Well-know retailer Target (NYSE: TGT) trades at just 11 times its earnings, which is about 60% cheaper than the S&P 500, which trades at about 28 times earnings, according to YCharts.
MRNA Seeks FDA Nod for Updated COVID-19 Vaccine
Moderna files with FDA for updated Spikevax aimed at the LP.8.1 variant, which makes up 70% of U.S. COVID-19 cases.
Roche Gets CHMP Nod for Itovebi Combo in the EU for Breast Cancer
RHHBY's Itovebi combo wins CHMP backing for PIK3CA-mutated breast cancer, showing strong survival benefits in phase III INAVO120 study.
Mentions: AZN
GILD Announces Positive Data on Trodelvy in First-Line Breast Cancer
Gileads Trodelvy shows significant improvement in PFS in phase III ASCENT-03 trial for first-line metastatic TNBC, reinforcing potential as backbone therapy.
Pfizer Inc. (PFE) Delivers Oncology Milestones with MesoC2 Debut and XTANDI Survival Boost
Pfizer Inc. (NYSE:PFE) has unveiled major advances in cancer research at the 2025 ASCO Annual Meeting, spotlighting robust five-year survival results for XTANDI (enzalutamide) combined with androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer. Data from the Phase 3 ARCHES trial show XTANDI plus ADT cuts the risk of death by 30%, with a […]
Down 63%, Should You Buy the Dip on Pfizer?
Pfizer has taken its lumps lately. It's time to wonder whether the stock can make a comeback.
Target Stock: Time to Panic?
Target missed estimates and cut its guidance in its first-quarter earnings report. Target (NYSE: TGT) has been one of the most disappointing retail stocks on the market recently. After another earnings report came in well below both analysts' and the company's expectations, Target seems as far away from a recovery as ever.
Why Webull Corp. (BULL) Crashed On Friday
We recently published a list of 10 Firms That Led Bloodbath Today. In this article, we are going to take a look at where Webull Corp. (NASDAQ:BULL) stands against other Friday’s worst-performing stocks. Webull Corp. saw its share prices decline by 8.89 percent on Friday to end at $12.30 apiece as investors took profits to […]
U.S. Pharmaceutical Imports Might Soon Face Tariffs: 3 Stocks That Could Tumble as a Result
There's little doubt these pharmaceutical companies' costs will soon be rising at least a little.
Regeneron Initial Data on Multiple Myeloma Drug Encouraging
REGN posts strong early data for linvoseltamab combos in relapsed/refractory multiple myeloma, with ORRs up to 90% and high complete response rates.
Roche Gets FDA Nod for Label Expansion of Susvimo for Third Indication
FDA approves RHHBY's Susvimo for diabetic retinopathy, its third indication, offering 9-month relief with one treatment.
Pfizer's 7.5% Dividend: Income Haven or House of Cards?
Pfizer's high dividend yield warrants scrutiny regarding its sustainability, given changing revenues and pipeline investments.
Pharma Stock Roundup: NVO CEO Resigns, SNY to Buy VIGL & More
NVO CEO exits amid pressure. Sanofi is set to buy VIGL. Pfizer inks $1.25B 3SBio deal. FDA okays Roche eye drug for new indication. Merck starts key cancer study.
Pfizer Stock Analysis: Buy, Sell, or Hold?
Building America's Tomorrow: 3 Long-Haul Investments to Consider
Berkshire Hathaway should continue its success even after Warren Buffett steps down as CEO. Enterprise Products Partners plays a critical role in the U.S. energy industry. Intuitive Surgical has strong long-term growth prospects in the robotic surgical systems market.
Cigna Announced a New Agreement for Copay Caps on Eli Lilly and Novo Nordisk Weight Loss Drugs
The Cigna Group (NYSE:CI)’s Evernorth division has announced a new deal with Novo Nordisk and Eli Lilly that will limit insured customers’ monthly out-of-pocket expenses for weight-loss drugs Zepbound and Wegovy to $200. Beginning in the second half of 2025, the program targets businesses that do not already cover these drugs because of their high […]
Was Jim Cramer Right About Pfizer Inc. (PFE)?
We recently published a list of Was Jim Cramer Right About These 12 Stocks? In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other stocks that Jim Cramer discusses. Back in 2024, on May 17, a caller asked about Pfizer Inc. (NYSE:PFE), which had struggled post-COVID. Cramer […]
Was Jim Cramer Right About DraftKings Inc. (DKNG)?
We recently published a list of Was Jim Cramer Right About These 12 Stocks? In this article, we are going to take a look at where DraftKings Inc. (NASDAQ:DKNG) stands against other stocks that Jim Cramer discusses. Back in 2024, on May 16, a caller asked about sports betting stocks ahead of football season at […]
Argentina's Milei unveils bold plan to lure billions in undeclared dollars back home
Argentina's government on Thursday unveiled an ambitious scheme to bring billions of undeclared U.S. dollars tucked under mattresses or stashed in foreign bank accounts back into the crisis-prone country, as libertarian President Javier Milei seeks to boost Argentina's low international currency reserves and stimulate the limping economy. “You can use them however you want, without having to prove where you got them from.”
Astellas and Pfizer's XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer
Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30% After a...
MRNA Stock Down on Withdrawal of FDA Filing for COVID-Flu Combo Shot
Moderna's voluntary withdrawal of the filing stems from the FDA's request for vaccine efficacy data from a phase III study on the experimental flu shot.
5 Low Price-to-Sales Stocks That Can Deliver Big Returns in 2025
The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like GDOT, JAKK, PCB, ROCK and PFE hold promise.
Pfizer Hits FDA Setback in Effort to Boost Prostate Cancer Drug
Pfizer Inc. failed to convince advisers to the US Food and Drug Administration to support a dramatic expansion in the use of its prostate cancer drug, a setback that could scuttle the company’s blockbuster ambitions for the treatment.
Bernstein Reaffirms Pfizer Rating After $6B Cancer Treatment Deal
Bernstein analysts reaffirmed their Market Perform rating and $30 price target for Pfizer Inc. (NYSE:PFE) on May 20, following the company’s recently disclosed $6 billion licensing deal with 3SBio Inc. to develop and market the cancer treatment SSGJ-707. While a notable venture at face value, the deal has raised questions about Pfizer’s continued collaboration with […]
Market Monitor News May 12 ( NRG Energy, Amazon, Meta Platforms UP - CVS Health DOWN)
Wall Street Surges on Temporary Trade Truce Between US and China
Which S&P500 stocks are the most active on Monday?
Looking for the most active stocks in the S&P500 index on Monday? Dive into today's session and discover the stocks that are dominating the trading activity and setting the pace for the market.
Top S&P500 movers in Monday's pre-market session
Get insights into the top gainers and losers in the S&P500 index of Monday's pre-market session.
Looking for the most active stocks in the S&P500 index on Friday?
Explore the S&P500 index on Friday and find out which stocks are the most active in today's session. Stay updated with the stocks that are capturing market interest.
What's going on in today's session: S&P500 most active stocks
Looking for the most active stocks in the S&P500 index on Thursday? Dive into today's session and discover the stocks that are dominating the trading activity and setting the pace for the market.